Prof. PeptideProf. Peptide

Chromium

Metabolic & Weight Loss

Last reviewed: May 26, 2026

Also Known As: Chromium picolinate, chromium polynicotinate, GTF chromium, trivalent chromium, Cr(III)

Supplement Class: Essential trace mineral / insulin-receptor cofactor (via chromodulin) / glycemic adjunct

Evidence Tier: Strong for T2D glycemic control — Anderson et al. 1997's dose-ranging RCT and Suksomboon et al. 2014's meta-analysis demonstrate significant HbA1c and fasting glucose reductions in diabetic populations. Moderate, responder-dependent, for insulin sensitivity by clamp methodology — Cefalu et al. 2010 reports benefit concentrated in more insulin-resistant subjects rather than a uniform effect. Cochrane 2013's weight-loss meta-analysis confirms a modest but real effect.

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is chromium?

Chromium is an essential trace mineral required in microgram amounts that functions as a cofactor for insulin signaling. It is incorporated into chromodulin (also called glucose tolerance factor / GTF), a small oligopeptide that binds the activated insulin receptor and amplifies its tyrosine kinase activity — improving GLUT4 translocation, glucose uptake into muscle and fat cells, and overall insulin sensitivity. Chromium has one of the deeper RCT bases of any metabolic mineral reviewed for this site, with Anderson et al. 1997 and Suksomboon et al. 2014's meta-analysis reporting significant HbA1c and fasting glucose reductions in type 2 diabetes populations. Cefalu et al. 2010's clamp-methodology trial adds an important nuance: chromium's insulin-sensitivity benefit was not consistent across all phenotypes, with clinical response concentrated in subjects with more elevated baseline glucose and HbA1c. The weight-loss evidence (Cochrane 2013) is modest but real. Chromium is discussed alongside GLP-1 receptor agonist peptides like Semaglutide and Tirzepatide as operating on different layers of the same metabolic system — peptides upstream at GLP-1 receptors and gastric emptying, chromium downstream at insulin-receptor signaling.

Reported benefits:

  • Reduced HbA1c and fasting glucose in T2D (Anderson et al. 1997, Suksomboon et al. 2014's meta-analysis)
  • Insulin-sensitivity improvement in more insulin-resistant subjects, per clamp-methodology data (Cefalu et al. 2010)
  • Modest weight loss in overweight populations (roughly 1 kg per Cochrane 2013)
  • Reduced carbohydrate cravings and food intake (Anton et al. 2008)
  • Improved lipid profile (LDL, total cholesterol) in dyslipidemic populations
  • Correction of dietary chromium gap common in processed-food-heavy diets

Common dose: 200–400 mcg/day chromium picolinate with a meal for general metabolic baseline; 500–1000 mcg/day (often split AM/PM) for T2D / insulin resistance protocols (the Anderson et al. 1997 high-dose arm). With food, ideally the largest carbohydrate-containing meal.

Reported safety considerations: Hypoglycemia risk when combined with insulin, sulfonylureas, or aggressive GLP peptide titration — glucose monitoring is standard guidance. Renal excretion means clinician coordination is standard guidance for kidney or liver disease. A cell-culture DNA-damage concern has not been reproduced in animal or human trials at typical doses.

On this page
  1. 1.How does chromium work?
  2. 2.What does the evidence say chromium does?
  3. 3.How is chromium dosed?
  4. 4.How chromium is taken
  5. 5.What does chromium stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about chromium
  8. 8.Product-quality considerations
  9. 9.Chromium FAQ
  10. 10.References
  11. 11.Published Studies

How does chromium work?

Chromium is reported to work primarily through insulin signaling — it is a cofactor for chromodulin (also called glucose tolerance factor / GTF), a small oligopeptide that binds to the insulin receptor and amplifies its tyrosine kinase activity. The result is discussed as more efficient downstream insulin signaling: better GLUT4 translocation, better glucose uptake into muscle and fat cells, and better suppression of hepatic glucose output. Secondary mechanisms include effects on lipid metabolism and CNS appetite/craving signaling.

  1. Chromodulin and insulin-receptor amplification. Chromium is incorporated into chromodulin (four chromium atoms per molecule), which binds the activated insulin receptor and enhances its tyrosine kinase activity. The downstream cascade — PI3K/Akt signaling, GLUT4 translocation, glycogen synthesis activation — is reported to be amplified, forming the core mechanism behind chromium's glycemic effects.
  2. GLUT4 translocation and glucose disposal. By amplifying insulin receptor signaling, chromium is reported to increase translocation of GLUT4 glucose transporters to muscle and adipose cell membranes — the same transporter exercise and metformin target.
  3. Lipid metabolism via insulin sensitization. Improved insulin signaling is discussed as reducing hepatic lipogenesis, enhancing triglyceride clearance, and modestly lowering LDL cholesterol in dyslipidemic populations, flowing downstream from the primary insulin-sensitization mechanism.
  4. CNS appetite and craving signaling. Some research suggests chromium influences serotonin and norepinephrine signaling, potentially reducing carbohydrate-specific cravings and binge-eating patterns. Anton et al. 2008 reports appetite and craving reductions in overweight women on 1000 mcg/day; this mechanism is less well-characterized than the insulin arm.
  5. Correction of dietary chromium gap. Modern diets are frequently reported as low in chromium, since food processing strips it from refined grains. Supplemental chromium is discussed as partly addressing a real dietary inadequacy in populations eating processed-heavy diets.

What does the evidence say chromium does?

Chromium has one of the deeper RCT bases of any metabolic mineral reviewed for this site — particularly in type 2 diabetes and impaired glucose tolerance. The strongest evidence is for HbA1c reduction and fasting glucose improvement in T2D, with response reported to be concentrated in more insulin-resistant subjects rather than uniform across all users.

  1. Type 2 diabetes glycemic control (Strong). Anderson et al. 1997 (n=180) reports dose-dependent HbA1c, fasting glucose, and insulin reductions at 200–1000 mcg/day chromium picolinate. Suksomboon et al. 2014's meta-analysis confirms a significant HbA1c-lowering effect across pooled trials.
  2. Insulin sensitivity in insulin-resistant populations (Moderate, responder-dependent). Cefalu et al. 2010 used euglycemic clamp methodology — a gold-standard insulin-sensitivity measurement — in patients with type 2 diabetes, reporting no consistent effect across all phenotypes; clinical response (a 10%+ insulin-sensitivity improvement) was reported to be concentrated in subjects with more elevated baseline fasting glucose and HbA1c. This responder/nonresponder pattern is a more precise characterization than a uniform benefit.
  3. Weight loss and body composition (Modest). The Cochrane 2013 meta-analysis reports a small but statistically significant roughly −1.0 kg average effect — real but modest, not GLP-class.
  4. Appetite and carbohydrate cravings (Moderate). Anton et al. 2008 reports reduced food intake, hunger, and fat cravings in overweight women. Smaller trials in atypical depression with carbohydrate craving report a similar directional signal.
  5. Lipid profile (Moderate). Reductions in total cholesterol and LDL are reported in dyslipidemic populations across trials, discussed as secondary to the glycemic arm.
  6. Healthy adults without metabolic dysfunction (Weak). Trial evidence in metabolically normal populations reports much smaller effects; chromium's benefit is reported as concentrated where insulin signaling is already compromised.

How is chromium dosed?

Chromium dosing in the literature reviewed is relatively straightforward: the published trial range is 200–1000 mcg/day of chromium picolinate. Higher doses are reserved for clinical T2D protocols; general metabolic-health use typically involves 200–400 mcg/day. Bioavailability of the picolinate form is reported as roughly 3× higher than chromium chloride and is the basis of most trial evidence.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. General health / metabolic baseline. 200–400 mcg/day chromium picolinate with a meal — used for mild insulin-sensitivity concerns or dietary chromium gaps.
  2. T2D / insulin resistance protocol. 500–1000 mcg/day, often split as 500 mcg twice daily with meals — the Anderson et al. 1997 high-arm protocol, the dose where the strongest HbA1c effect is reported.
  3. Weight-management adjunct. 400–600 mcg/day with meals, matching the dose range of weight-loss trials.
  4. Cravings-specific use. 600–1000 mcg/day — the dose Anton et al. 2008 used to report appetite and craving reductions in overweight women.

Reported timeline: glycemic effects build over 4–8 weeks (HbA1c is a roughly 90-day average, so trial results emerge at the 2–3 month mark). Subjective craving and appetite effects may emerge within 2–4 weeks; acute same-day effects are not reported.

Label math. Most chromium supplements are dosed in mcg (micrograms), not mg. A 200 mcg capsule provides 200 micrograms of elemental chromium — within the range used in the trials reviewed. Proprietary blends that list chromium as a sub-component without specifying mcg per serving don't allow independent verification of dose.

How chromium is taken

Chromium is taken orally, typically as picolinate capsules or tablets; powder is uncommon. The points below cover practical details discussed in the sources reviewed.

AspectReported
FrequencyOnce daily for baseline use; twice-daily split dosing for higher-dose T2D protocols.
Best time of dayWith the largest carbohydrate-containing meal, since the postprandial insulin response is where chromium's amplification effect is reported to operate. For split dosing: AM with breakfast plus PM with dinner.
FoodWith food, particularly meals containing carbohydrates — the effect is discussed as meal-coupled.
FormChromium picolinate is the trial-validated form with the best bioavailability; chromium polynicotinate is an alternative; chromium chloride has poor absorption. "GTF chromium" (brewer's yeast complex) is a food-source alternative with less standardization.
Standardization markerA label reading "chromium picolinate" with mcg of elemental chromium per serving explicitly disclosed (e.g., "200 mcg chromium as chromium picolinate") is the clearer standard. Third-party testing (USP, NSF, ConsumerLab) is a secondary check.
CyclingNo cycling is reported as required — continuous daily use is the trial-validated model, with no documented tolerance development.

What does chromium stack with?

Chromium is discussed alongside the broader metabolic and glycemic-control toolkit. The insulin-sensitization mechanism is reported as complementary to GLP-1 receptor agonism (peptides), AMPK activation (berberine, metformin), and other insulin-sensitivity adjuncts.

With peptides

Chromium is discussed alongside the GLP-cluster metabolic peptides. Semaglutide (a GLP-1 receptor agonist) and tirzepatide (a dual GLP-1/GIP agonist) work upstream — enhancing glucose-dependent insulin secretion, slowing gastric emptying, and reducing appetite via central pathways. Retatrutide adds glucagon receptor agonism for a broader metabolic profile. Chromium is discussed as operating downstream at the insulin-receptor signaling step — amplifying the action of whatever insulin is secreted, a mechanistically additive layer. GLP peptides can produce hypoglycemia when combined with sulfonylureas or insulin; adding chromium adds another small glucose-lowering effect, so closer monitoring during titration is standard guidance. No direct drug interaction is documented in the sources reviewed.

With supplements

  1. Berberine — an AMPK activator with metformin-comparable glycemic effects, a different mechanism (AMPK vs insulin-receptor amplification) commonly combined for comprehensive glucose support.
  2. Alpha lipoic acid — additional insulin sensitization plus antioxidant support, frequently paired with chromium in metabolic protocols.
  3. Magnesium — a cofactor for enzymes involved in glucose metabolism; deficiency is common and is reported to impair insulin signaling.
  4. Vitamin D3 — vitamin D status is reported to correlate with insulin sensitivity, with correction of deficiency discussed as a foundational metabolic intervention.
  5. Cinnamon (Ceylon variety) — mild insulin-sensitizing effects reported in some trials, a common co-occupant in metabolic stacks.

With lifestyle factors

  1. Resistance training and aerobic exercise. Exercise is reported to activate GLUT4 translocation independently; chromium is discussed as amplifying the insulin-signaling-mediated arm of glucose disposal additively.
  2. Whole-foods, lower-refined-carb diet. The trial evidence is built on chromium alongside standard dietary care; chromium is discussed as supporting the diet rather than substituting for it.
  3. Meal timing. Dosing with the largest carbohydrate-containing meal is standard guidance, since that is when the postprandial insulin response — and chromium's amplification effect — is largest.
  4. Sleep. Sleep deprivation is reported to impair insulin sensitivity; chromium is not discussed as compensating for chronic poor sleep.

Side effects and interactions

Chromium picolinate has a favorable safety record in the clinical trials reviewed. The main considerations reported are mild GI effects, a cell-culture DNA-damage concern not reproduced in vivo, and additive hypoglycemic potential with other glucose-lowering interventions.

Common (mostly transient)

  1. Mild GI discomfort — occasional nausea or stomach upset, especially on an empty stomach, reported to resolve with food.
  2. Headache — uncommon, dose-related at the higher end (1000 mcg+).
  3. No documented serious adverse events at standard supplemental doses across the human RCT base reviewed.

Less common (watch-list)

  1. Hypoglycemia risk — possible when combined with sulfonylureas, insulin, or aggressive GLP peptide titration; closer glucose monitoring during the first 4–6 weeks of combined use is standard guidance.
  2. Kidney or liver disease — chromium is renally excreted; clinician coordination is standard guidance.
  3. A theoretical DNA-damage concern at very high doses observed in some in vitro cell-culture studies has not been reproduced in animal or human trials at typical supplemental doses; practical relevance is reported as low.

Drug and supplement interactions

  1. Insulin and sulfonylureas. An additive glucose-lowering effect is reported; glucose monitoring during titration and possible clinician-directed medication adjustment is standard guidance.
  2. Metformin. Additive insulin-sensitization is reported, generally well tolerated together.
  3. GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide). Reported as compatible and mechanistically additive; watching for hypoglycemia during peptide titration is standard guidance if also on sulfonylureas/insulin.
  4. Levothyroxine (thyroid hormone) — chromium may modestly reduce thyroid hormone absorption; separating doses by 4 hours is a common mitigation.
  5. Pregnancy and breastfeeding — data is limited; clinician coordination is standard guidance.

What isn't established about chromium

Chromium has one of the more solid metabolic-mineral RCT bases reviewed for this site, but several questions remain open — particularly around population specificity, long-term safety at high doses, and the magnitude of effect in metabolically healthy users.

Effect-size variability by population. The strongest trial evidence is in T2D, insulin resistance, and overweight populations. Cefalu et al. 2010 reports clinical response was concentrated in subjects with more elevated baseline fasting glucose and HbA1c — chromium is not reported as producing a consistent effect across all phenotypes.

Multi-year safety at 1000 mcg/day. Trial data extends to 8–12 months at the higher dose. Multi-year use at 1000 mcg/day is not characterized in controlled trials reviewed.

DNA-damage signal from cell culture. Some in vitro studies have raised concerns about chromium picolinate causing DNA damage at very high doses; this has not been reproduced in animal or human trials at typical supplemental doses reviewed.

Weight-loss clinical significance. The Cochrane 2013 meta-analysis reports a statistically significant but small (roughly −1.0 kg) weight-loss effect. Whether this is clinically meaningful, especially relative to GLP peptides producing 15–20%+ weight reductions, is not established.

Form-equivalence beyond picolinate. Most evidence reviewed is on chromium picolinate. Whether chromium polynicotinate, GTF (brewer's yeast), or food-source chromium produce equivalent metabolic effects is mechanistically plausible but not rigorously tested head-to-head in the sources reviewed.

Dietary chromium status. Standard chromium-status tests are not routinely available, so users cannot easily verify deficiency before supplementing. Trial evidence suggests chromium's effect concentrates in insulin-resistant populations regardless of measured chromium status.

Product-quality considerations

Chromium picolinate is widely available over-the-counter at low cost. The quality bar is moderate — picolinate form is what the trial evidence rests on, and clean disclosure of mcg per serving is the main quality marker.

Quality markers reported in the category

  • Chromium picolinate form explicitly disclosed — the form every major positive RCT used.
  • Mcg of elemental chromium per serving disclosed (e.g., "200 mcg chromium as chromium picolinate").
  • Third-party testing — USP, NSF, or ConsumerLab certification signals independent verification.
  • cGMP-certified manufacturing facility.
  • No proprietary blends that obscure the actual chromium dose alongside fillers.
  • Chromium chloride is generally avoided given its poor bioavailability relative to the form clinical trials are built on.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Chromium FAQ

How do chromium picolinate, polynicotinate, and GTF compare?

Chromium picolinate is the most extensively studied form, with the deepest human RCT base (Anderson et al. 1997, Cefalu et al. 2010, multiple meta-analyses) — the form most supplement evidence is built on. Chromium polynicotinate is also reasonably absorbed, though its trial evidence is thinner. Chromium chloride has poor bioavailability. "GTF chromium" (glucose tolerance factor) refers to a brewer's-yeast-derived chromium complex, sometimes used as a food-based alternative, though its standardization and bioavailability are less characterized than picolinate's.

Does chromium help with weight loss?

Modestly. A 2013 Cochrane review reports chromium produced a small but statistically significant reduction in body weight versus placebo (roughly 1 kg average across trials), with a greater effect in overweight and obese individuals. The mechanism discussed is partly carbohydrate-craving reduction and partly insulin-sensitization-mediated improvements in glucose disposal. This is not GLP-1-class weight loss (semaglutide/tirzepatide produce 15–20%+ reductions) — chromium is discussed as a modest adjunct rather than a standalone weight-loss intervention.

What dose range is discussed as safe?

Published research uses 200–1000 mcg/day with a consistent safety record; doses up to 1000 mcg/day for 8+ months in T2D trials produced no concerning signals. A cell-culture concern about chromium picolinate causing DNA damage at very high doses has not been reproduced in animal or human studies at typical supplemental doses. The FDA Adequate Intake (AI) is 25–35 mcg/day from diet; supplemental doses several times higher are routine in clinical research. Users with kidney or liver disease are generally advised to be more cautious, since chromium is renally excreted.

Is chromium compatible with metformin or insulin?

Generally, yes, with closer glucose monitoring. Chromium's insulin-potentiating effect is discussed as additive with both metformin and insulin therapy. Published T2D trials included patients on these medications and reported additive benefit in responders. Clinician coordination is standard guidance for dose adjustments, since combined use can modestly lower glucose further and requires monitoring for hypoglycemia risk.

Does chromium stack with Semaglutide, Tirzepatide, or Retatrutide?

The mechanism layering is discussed as clean. Semaglutide, tirzepatide, and retatrutide are GLP-1 (and GIP/glucagon) receptor agonists that reduce appetite, slow gastric emptying, and improve glucose-dependent insulin secretion. Chromium is discussed as operating downstream at the insulin-receptor signaling step, amplifying the action of whatever insulin is secreted — different layers of the metabolic system, same overall direction. GLP peptides can cause hypoglycemia in patients also on sulfonylureas or insulin; adding chromium adds another small glucose-lowering effect, so closer glucose monitoring during titration is standard guidance. No direct drug interaction is documented in the sources reviewed.

Does chromium reduce sugar cravings?

Some research suggests it does, particularly for carbohydrate-specific cravings. A handful of trials in atypical depression with carbohydrate craving and in binge-eating populations report chromium picolinate modestly reduced craving intensity and binge frequency versus placebo. The proposed mechanism involves serotonin and norepinephrine signaling in addition to the insulin-sensitization arm; effect sizes are modest and the trial base is smaller than the T2D evidence.

Is cycling or continuous use discussed for chromium?

Continuous daily use is the model the trial evidence supports. The Anderson et al. 1997 trial used 8 months of continuous daily dosing; subsequent T2D trials extend to 12+ months with no concerning signals. There is no pharmacological rationale for cycling chromium the way stimulants are cycled, since the mechanism does not involve receptor downregulation.

Is chromium useful for someone metabolically healthy already?

The trial evidence suggests less benefit for this population. The strongest trial evidence is in people with type 2 diabetes, impaired glucose tolerance, or insulin resistance — populations where insulin signaling is already compromised. Cefalu et al. 2010 specifically reports that clinical response to chromium correlated with baseline insulin resistance severity, with more insulin-resistant subjects more likely to respond; in metabolically healthy users the signal is reported as much smaller.

References

  1. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes. 1997;46(11):1786-1791. https://pubmed.ncbi.nlm.nih.gov/9356027/
  2. Suksomboon N, Poolsup N, Yuwanakorn A. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. J Clin Pharm Ther. 2014;39(3):292-306. https://pubmed.ncbi.nlm.nih.gov/24635480/
  3. Tian H, Guo X, Wang X, et al. Chromium picolinate supplementation for overweight or obese adults. Cochrane Database Syst Rev. 2013;(11):CD010063. https://pubmed.ncbi.nlm.nih.gov/24293292/
  4. Cefalu WT, Rood J, Pinsonat P, et al. Characterization of the metabolic and physiologic response to chromium supplementation in subjects with type 2 diabetes mellitus. Metabolism. 2010;59(5):755-762. https://pubmed.ncbi.nlm.nih.gov/20022616/
  5. Anton SD, Morrison CD, Cefalu WT, et al. Effects of chromium picolinate on food intake and satiety. Diabetes Technol Ther. 2008;10(5):405-412. https://pubmed.ncbi.nlm.nih.gov/18715218/
  6. Vincent JB. The biochemistry of chromium. J Nutr. 2000;130(4):715-718. https://pubmed.ncbi.nlm.nih.gov/10736319/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

Diabetes · 1997Open Access
Elevated Intakes of Supplemental Chromium Improve Glucose and Insulin Variables in Individuals with Type 2 Diabetes →

Anderson RA, Cheng N, Bryden NA, et al.

An 8-month randomized double-blind placebo-controlled trial of chromium picolinate (200 mcg or 1000 mcg daily) in 180 Chinese patients with type 2 diabetes. Reports the 1000 mcg dose produced significant reductions in HbA1c, fasting blood glucose, 2-hour postprandial glucose, fasting insulin, and total cholesterol versus placebo, with dose-dependent magnitude. A foundational human trial for chromium's metabolic effects.

Journal of Clinical Pharmacy and Therapeutics · 2014Open Access
Systematic Review and Meta-Analysis of the Efficacy and Safety of Chromium Supplementation in Diabetes →

Suksomboon N, Poolsup N, Yuwanakorn A

A meta-analysis of RCTs of chromium supplementation in adults with type 2 diabetes. Reports chromium produced statistically significant reductions in HbA1c and fasting plasma glucose versus placebo, with a more pronounced effect for chromium picolinate than other chromium forms, and moderate heterogeneity across trials.

Cochrane Database of Systematic Reviews · 2013Open Access
Chromium Picolinate Supplementation for Overweight or Obese Adults →

Tian H, Guo X, Wang X, et al.

A Cochrane systematic review and meta-analysis of RCTs of chromium picolinate in overweight or obese adults. Reports a small but statistically significant reduction in body weight (mean roughly −1.0 kg) versus placebo, with the reviewers concluding the magnitude was modest and clinical significance uncertain.

Metabolism · 2010Paywalled
Characterization of the Metabolic and Physiologic Response to Chromium Supplementation in Subjects with Type 2 Diabetes Mellitus →

Cefalu WT, Rood J, Pinsonat P, et al.

A placebo-controlled trial of 1000 mcg/day chromium picolinate in patients with type 2 diabetes, using euglycemic clamps to assess insulin sensitivity. Reports there was not a consistent effect of chromium across all phenotypes — clinical response (insulin-sensitivity improvement of 10%+) was concentrated in subjects with more elevated baseline fasting glucose and HbA1c, i.e., more insulin-resistant subjects. Myocellular lipids were significantly lower in the chromium group. The trial's responder/nonresponder framing is the more precise characterization of chromium's clamp-measured effect than a uniform-benefit description.

Diabetes Technology & Therapeutics · 2008Open Access
Effects of Chromium Picolinate on Food Intake and Satiety →

Anton SD, Morrison CD, Cefalu WT, et al.

A placebo-controlled trial of 1000 mcg/day chromium picolinate in overweight women with carbohydrate cravings. Reports chromium reduced food intake, hunger ratings, and fat cravings versus placebo, extending chromium's appetite and craving effects to a healthy overweight population rather than only metabolically diseased patients.

Insulin SensitivityBlood SugarChromodulinT2D AdjunctTrace MineralCarb Cravings

Related Supplements

BerberineAlpha Lipoic AcidMagnesiumVitamin D3Green Tea Extract

We may earn commissions from peptide vendor affiliate links.

Have a question about Chromium? Send us an email